Browse studies

Find your next paid study

3,851 recruiting studies matching your filters

Pilot Randomized Controlled Trial of a Remote Monitoring and Symptom Management Intervention (ASSIST) Among Patients Receiving Systemic Therapy

The goal of this clinical trial is to learn if an artificial intelligence phone application called ASSIST can help patients receiving cancer treatment. The ma…

Breast Cancer (Locally Advanced or Metastatic)LymphomaColorectal Cancer

Estimated

~$10 – $7,500

Patrick C. Johnson, MDNCT07553572

Phase 1

Adoptive Immunotherapy for Advanced MUC1* Positive Breast Cancer With Autologous T Cells Engineered to Express a Chimeric Antigen Receptor, huMNC2-CAR44 or huMNC2-CAR22, Specific for a Cleaved Form of MUC1 (MUC1*)

Phase I/II study of adoptive immunotherapy for advanced MUC1\* positive breast cancer with autologous T cells engineered to express either a chimeric antigen r…

Metastatic Breast Cancer

Estimated

~$10 – $8,750

Minerva Biotechnologies CorporationNCT04020575

Phase 2

Adjuvant Sacituzumab Govitecan Plus Nivolumab in Patients With Muscle-Invasive Urothelial Carcinoma at High-Risk for Recurrence

This is a phase 2 study, single-arm study of adjuvant combination therapy with Sacituzumab Govitecan and Nivolumab in patients with muscle-invasive urothelial …

Urothelial CarcinomaMuscle-invasive Bladder Cancer

Estimated

~$10 – $6,250

University of California, IrvineNCT06682728

Observational

Engagement of Veterans With Lung Cancer (EVLC)

This research study will help our understanding of whether additional support for Veterans with lung cancer can improve their quality of life.

Lung Cancer (NSCLC)Lung AdenocarcinomaLung Cancer, Non-Small Cell+3 more

Estimated

~$10 – $5,625

Palo Alto Veterans Institute for ResearchNCT07219251

Phase 1

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors

This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor mic…

Head and Neck Squamous Cell CarcinomaSoft Tissue Sarcoma AdultTriple Negative Breast Cancer

Estimated

~$10 – $8,750

Pure Biologics S.A.NCT06700070

An Observational Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC)

This is a multi-center observational study in subjects with a diagnosis of small cell lung cancer. Screening and/or medical record review for symptoms associat…

Small Cell Lung Cancer ( SCLC )Lambert Eaton Myasthenic Syndrome (LEMS)

Estimated

~$10 – $1,125

Addario Lung Cancer Medical InstituteNCT07075627

Phase 2

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.

Breast Cancer

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT03990896

The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients

This study is being done to learn more about breast cancer patients' experiences with sleep changes during cancer treatment, identify possible reasons for poor…

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+2 more

Estimated

~$10 – $750

Ohio State University Comprehensive Cancer CenterNCT07341503

Phase 1

A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Locally Advanced or Metastatic Cancers Following One or More Prior Therapies

This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. r…

Advanced CancerAdvanced Solid TumorMelanoma+15 more

Estimated

~$10 – $8,750

7 Hills Pharma, LLCNCT06362369

Phase 2

Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer

This randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (…

Breast CancerLocally Advanced Breast CancerCognitive Impairment+5 more

Estimated

~$10 – $6,250

UNC Lineberger Comprehensive Cancer CenterNCT06727773

Phase 4

Gadopiclenol (Elucirem): A New Gadolinium Based Contrast Agent With High Relaxivity for Increased Contrast and Improved Differentiation of Clinically Significant Prostate Cancer on Contrast Enhanced MRI: A Prospective Study.

The fundamental aim of this study is to show that the novel contrast agent Gadopiclenol (Elucirem), with its high relaxivity, facilitates increased contrast en…

Prostate Cancer

Estimated

~$10 – $6,250

Columbia UniversityNCT06226129

Phase 3

Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. …

CardiotoxicityHER2/Neu PositiveMetastatic Malignant Neoplasm in the Brain+2 more

Estimated

~$10 – $7,500

SWOG Cancer Research NetworkNCT03418961